These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35662291)

  • 1. Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan.
    Shao YJ; Hong JH; Chen CK; Huang CY
    Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):722-729. PubMed ID: 35662291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
    Chen DY; Su PJ; See LC; Liu JR; Chuang CK; Pang ST; Tseng CN; Chen SW; Hsieh IC; Chu PH; Lin YC; Hsu CL; Chang JW; Lin MS; Pang JS; Hsieh MJ; Huang WK
    Prostate; 2021 Sep; 81(12):902-912. PubMed ID: 34196430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.
    Dragomir A; Touma N; Hu J; Perreault S; Aprikian AG
    J Natl Compr Canc Netw; 2023 Feb; 21(2):163-171. PubMed ID: 36791755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
    Higano CS
    Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
    Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
    Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study.
    Chen DY; See LC; Liu JR; Chuang CK; Pang ST; Hsieh IC; Wen MS; Chen TH; Lin YC; Liaw CC; Hsu CL; Chang JW; Kuo CF; Huang WK
    J Clin Oncol; 2017 Nov; 35(32):3697-3705. PubMed ID: 28968166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist.
    Margel D; Ber Y; Peer A; Shavit-Grievink L; Pinthus JH; Witberg G; Baniel J; Kedar D; Rosenbaum E
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):177-185. PubMed ID: 32737420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
    Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
    Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
    Keating NL; O'Malley AJ; Freedland SJ; Smith MR
    J Natl Cancer Inst; 2010 Jan; 102(1):39-46. PubMed ID: 19996060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design.
    Melloni C; Slovin SF; Blemings A; Goodman SG; Evans CP; Nilsson J; Bhatt DL; Zubovskiy K; Olesen TK; Dugi K; Clarke NW; Higano CS; Roe MT;
    JACC CardioOncol; 2020 Mar; 2(1):70-81. PubMed ID: 34396210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Cardiovascular Risks of Gonadotropin-releasing Hormone Agonists and Antagonists: A Population-based Cohort Study.
    Chan JSK; Lee YHA; Hui JMH; Liu K; Dee EC; Ng K; Tang P; Tse G; Ng CF
    Clin Oncol (R Coll Radiol); 2023 Jun; 35(6):e376-e383. PubMed ID: 37031076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer.
    Cirne F; Aghel N; Petropoulos JA; Klotz L; Lenihan DJ; Saad F; Pinthus J; Leong DP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):253-262. PubMed ID: 33470403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis.
    Gu L; Li X; Liu W
    Front Endocrinol (Lausanne); 2023; 14():1157857. PubMed ID: 37065739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
    Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
    Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer.
    Ng CT; Bonilla HMG; Bryce AH; Singh P; Herrmann J
    Curr Cardiol Rep; 2023 Aug; 25(8):889-899. PubMed ID: 37490155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Proteomics: A Post Hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist vs GnRH Agonist among Men with Advanced Prostate Cancer.
    Lifshitz K; Ber Y; Shenhar C; Nillson J; Peer A; Rosenbaum E; Baniel J; Kedar D; Ben Zadok OI; Margel D
    J Urol; 2021 Oct; 206(4):952-959. PubMed ID: 34032505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.
    Albertsen PC; Klotz L; Tombal B; Grady J; Olesen TK; Nilsson J
    Eur Urol; 2014 Mar; 65(3):565-73. PubMed ID: 24210090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice.
    Davey P; Kirby MG
    World J Urol; 2021 Feb; 39(2):307-315. PubMed ID: 32979057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.